Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
  • Patent number: 10752902
    Abstract: The disclosure relates to, among other things, agents that modulate the homophilic interaction between two CRACC polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal. Also featured are screening methods for identifying additional agents capable of modulating the activation of an immune cell exposed to an antigen.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: August 25, 2020
    Assignee: Board of Trustees of Michigan State University
    Inventors: Andrea Amalfitano, Yasser A. Aldhamen
  • Patent number: 10695426
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: June 30, 2020
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Leena Das-Young, Keith David Wilner, Steffan Nicholas Ho
  • Patent number: 10688186
    Abstract: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: June 23, 2020
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Patent number: 10689444
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 23, 2020
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 10647770
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 12, 2020
    Inventors: Shiro Shibayama, Masamichi Imai
  • Patent number: 10640567
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 5, 2020
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Patent number: 10624950
    Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 21, 2020
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Patent number: 10610582
    Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 7, 2020
    Assignee: PCI BIOTECH AS
    Inventors: Anders Hogset, Pal Johansen
  • Patent number: 10604567
    Abstract: Disclosed herein are antibodies specific for erythroferrone and assays comprising the antibodies. Also disclosed are methods for using the assays for the diagnosis or monitoring of disease.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 31, 2020
    Inventors: Mark Westerman, Huiling Han, Vaughn Ostland
  • Patent number: 10590195
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 17, 2020
    Assignee: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Patent number: 10519242
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 31, 2019
    Assignee: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • Patent number: 10512687
    Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 24, 2019
    Assignees: Colorado State University Research Foundation, The Regents of the University of Colorado, a body corporate
    Inventors: Steven Dow, Michael R. Lappin, William H. Wheat, Lyndah Chow, Daniel P. Regan, Thomas J. Anchordoquy
  • Patent number: 10509033
    Abstract: Provided are a method for diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP), in particular, a diagnostic method for specifically diagnosing a group having a specific pathophysiology among CIDPs, and a kit and a biomarker for use in such a diagnosis. The diagnostic method for diagnosing CIDP of the present invention includes a step of measuring an anti-neurofascin 155 antibody contained in a sample.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Kyushu University, National University Corporation
    Inventors: Junichi Kira, Nobutoshi Kawamura, Ryo Yamasaki, Dai Matsuse, Hidenori Ogata
  • Patent number: 10466325
    Abstract: The disclosure relates to a method for determining a sequence information element of a magnetic resonance sequence, a computer program product and an evaluation unit for performing such a method, and also a magnetic resonance device having such an evaluation unit. The method includes a determination of the sequence information element based on at least one pattern of the magnetic resonance sequence.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: November 5, 2019
    Assignee: Siemens Healthcare GmbH
    Inventors: Andreas Greiser, David Grodzki, Daniel Nico Splitthoff
  • Patent number: 10458986
    Abstract: The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: October 29, 2019
    Inventor: Salvador Macip
  • Patent number: 10444241
    Abstract: The application provides methods of diagnosis, prognosis, prophylasxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 15, 2019
    Inventors: Tina Albertson, Maria L. Smith
  • Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • Patent number: 10420846
    Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 24, 2019
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Annelise Brigitte Vuidepot, Yi Li
  • Patent number: 10420751
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 24, 2019
    Assignee: MedRegen, LLC
    Inventors: Zhaoli Sun, Xuhang Li
  • Patent number: 10407513
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: September 10, 2019
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood
  • Patent number: 10408820
    Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 10, 2019
    Inventors: Vineet Gupta, M. Amin Arnaout
  • Patent number: 10400043
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 3, 2019
    Assignee: Biogen, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 10383917
    Abstract: Provided is an agent for the treatment of an autoimmune disease, the agent comprising C1q/TNF-related protein 3 (CTRP3), and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRPb3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 20, 2019
    Inventors: Yoichiro Iwakura, Masanori Murayama
  • Patent number: 10350242
    Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: July 16, 2019
    Inventor: Michael Har-Noy
  • Patent number: 10336829
    Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 2, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
  • Patent number: 10316095
    Abstract: Formulations of anti-VLA-1 antibodies are described.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: June 11, 2019
    Assignee: Santarus, Inc.
    Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
  • Patent number: 10316085
    Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 11, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank
  • Patent number: 10293059
    Abstract: This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding a therapeutic gene that blocks allergic reactions. The invention is also directed to a composition comprising the vector and method of using the vector to reduce or inhibit an immune response or allergic reaction to an allergen in a mammal.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: May 21, 2019
    Inventors: Ronald G. Crystal, Odelya E. Pagovich, Maria J. Chiuchiolo
  • Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Patent number: 10280208
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 7, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • Patent number: 10253095
    Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: April 9, 2019
    Inventors: Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
  • Patent number: 10245327
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 2, 2019
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10246510
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 2, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Benjamin Rossi, Hélène Sicard, Carine Paturel
  • Patent number: 10196616
    Abstract: An altered avian NDV that contains the coding sequence of avian interleukin-4 (IL-4), or a portion thereof, in the reverse orientation suppresses in-ovo IL-4 production via RNAi when administered to embryonic birds. An immunogenic composition containing this altered NDV is included in this invention. The altered avian NDV can, optionally contain a polynucleotide encoding a heterologous antigen from a heterologous avian pathogen and can produce said heterologous antigen in-ovo.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: February 5, 2019
    Assignees: The United States of America, as represented by the Secretary of Agriculture, University of Georgia Research Foundation, Inc.
    Inventors: Claudio L. Afonso, Valerie C. Marcano, Nany Stivalis Cardenas Garcia, Qingzhong Yu, Tonya L. Taylor
  • Patent number: 10189906
    Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: January 29, 2019
    Inventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
  • Patent number: 10174124
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 8, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
  • Patent number: 10106607
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 23, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Patent number: 10086046
    Abstract: The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (TReg) in an organism and various methods in which the agents according to the invention are used.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: October 2, 2018
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Daniela Paulsen, Nina Brunner, Dorothy Bray
  • Patent number: 10086042
    Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: October 2, 2018
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
  • Patent number: 10077312
    Abstract: The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: September 18, 2018
    Assignee: Numab Therapeutics AG
    Inventors: David Urech, Tea Gunde, Sebastian Meyer
  • Patent number: 10034939
    Abstract: In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: July 31, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
  • Patent number: 10016458
    Abstract: The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: July 10, 2018
    Assignee: Baystate Health, Inc.
    Inventor: Sabyasachi Sen
  • Patent number: 10000545
    Abstract: The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 19, 2018
    Inventors: Xavier Nassif, Sandrine Bourdoulous, Olivier Join-Lambert
  • Patent number: 9982023
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: May 29, 2018
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Carl F. Ware, John Sedy
  • Patent number: 9963508
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 8, 2018
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 9963497
    Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
    Type: Grant
    Filed: December 7, 2014
    Date of Patent: May 8, 2018
    Inventors: Raymond Kaempfer, Anat Shirvan, Gila Arad
  • Patent number: 9950035
    Abstract: Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII, Compositions may also contain white blood cells and platelets.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 24, 2018
    Assignee: Biomet Biologics, LLC
    Inventors: Jeffrey R. Binder, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey, Jennifer E. Woodell-May
  • Patent number: 9932402
    Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 3, 2018
    Assignee: NKT Therapeutics Inc.
    Inventors: Alemseged Truneh, Francis Joseph Carr, Timothy David Jones, James P. Gregson
  • Patent number: 9913830
    Abstract: The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 13, 2018
    Inventors: Todd M. Brusko, Benjamin G. Keselowsky, Judit Cserny